Michael Byrnes, Chief Financial Officer at eFFECTOR Therapeutics, Inc. (EFTR), bought 25,000 shares at $1.33 ($33K) on 2022-06-07, disclosed to the SEC on 2022-06-07.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Several strong factors at once. The rarest rating we give.
| Filing → |
| OCRX | BUY | 2015-05-06 | $9K | — | Filing → |
| OCRX | BUY | 2014-10-02 | $10K | — | Filing → |